Genzyme Builds New Manufacturing Facility As Takeover Deadline Approaches
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgium-based plant will be used to manufacture Myozyme and Lumizyme for Pompe disease, a franchise that Genzyme says has the potential to become a blockbuster.
You may also be interested in...
Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21
Less than 1% of outstanding shares had been tendered as of Dec. 10 deadline.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.